Eiger BioPharmaceuticals is focused on the development and commercialization of first-in-class targeted therapies for serious rare and ultra-rare diseases
We are committed to more rapidly delivering important medicines to patients with serious rare and ultra-rare diseases through developing first-in-class, well-characterized drugs acting on newly identified or novel targets
Eiger has discovered untapped therapeutic potential of molecules with well understood safety profiles with the goal of developing medications for life-threatening diseases that have no approved treatments.
*Required fields
Sign up to recieve email alerts about how Eiger continues to refine drug development